| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2001.19.1.213 |
| P698 | PubMed publication ID | 11134215 |
| P2093 | author name string | A S Pappo | |
| E Lyden | |||
| E Wiener | |||
| J Breneman | |||
| J Meza | |||
| L Teot | |||
| T Vietti | |||
| W Crist | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | teenager | Q1492760 |
| rhabdomyosarcoma | Q1898141 | ||
| P304 | page(s) | 213-219 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study | |
| P478 | volume | 19 |
| Q86364779 | A Modified Protocol with Vincristine, Topotecan, and Cyclophosphamide for Recurrent/Progressive Ewing Sarcoma Family Tumors |
| Q45274607 | A case report of rhabdomyosarcoma of the uterus associated with uterine inversion |
| Q33418620 | A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors |
| Q80510573 | Biology and therapy of malignant solid tumors in childhood |
| Q84198050 | Concurrent radiation with irinotecan and carboplatin in intermediate‐ and high‐risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study |
| Q34959107 | Congenital rhabdomyosarcoma of shoulder |
| Q36118405 | Current chemotherapeutic strategies for rhabdomyosarcoma |
| Q46446193 | Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma |
| Q45911250 | Escalating Topotecan in Combination with Treosulfan has Acceptable Toxicity in Advanced Pediatric Sarcomas |
| Q37132373 | Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee |
| Q34073784 | Initial testing of topotecan by the pediatric preclinical testing program. |
| Q44251162 | Management of alveolar rhabdomyosarcoma of the orbit |
| Q39564978 | Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy |
| Q92588601 | Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated |
| Q37021234 | Optimal management strategies for rhabdomyosarcoma in children |
| Q37337884 | PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis |
| Q52311090 | Patient-derived xenograft models in musculoskeletal malignancies. |
| Q37838445 | Pharmacotherapy for pediatric soft-tissue sarcomas |
| Q34131807 | Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study |
| Q36881113 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group |
| Q50421735 | Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol |
| Q37172346 | Primary pulmonary rhabdomyosarcoma in an adult: a case report and review of the literature |
| Q33577061 | Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972-2005: A report from the Children's Oncology Group |
| Q34618356 | Primary rhabdomyosarcoma of the diaphragm: case report and literature review. |
| Q36022696 | Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. |
| Q34281235 | Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group |
| Q41607004 | Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy |
| Q34589401 | Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors |
| Q42549626 | Rhabdomyosarcoma of the posterior chest wall in a newborn: a case report |
| Q60021362 | Sarcomas More Common in Children |
| Q34666372 | Soft-tissue sarcoma in childhood and adolescence |
| Q40177656 | The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma |
| Q34462986 | The Development of Camptothecin Analogs in Childhood Cancers |
| Q36674058 | The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols |
| Q40923985 | The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group |
| Q35548365 | The development of VAC chemotherapy in Rhabdomyosarcoma: What does one do for an encore? |
| Q80510499 | Topoisomerase I interactive agents |
| Q33400825 | Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity |
| Q50353862 | Topotecan for pediatric patients with resistant and recurrent solid tumors |
| Q35154422 | Treatment modalities of bladder/prostate rhabdomyosarcoma: a review |
| Q53657080 | Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). |
| Q44046635 | Vincristine, Irinotecan, and Temozolomide for Treatment of Relapsed Alveolar Rhabdomyosarcoma |
| Q37412294 | Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. |
| Q33343211 | Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma |
Search more.